Related Experiment Video

Updated: Aug 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting ADAM15 in cancer: from dual-faced biology to emerging therapies

Ali El-Far1, Binghui Song2, Junjiang Fu1

  • 1Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China; Innovative Institute for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China.

Drug Discovery Today
|July 21, 2026
PubMed

Insights

A disintegrin and metalloproteinase 15 (ADAM15) has a dual role in cancer. This review explores its mechanisms, including exosomal communication and RNA regulation, and therapeutic strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • ADAM15 is a cell-surface protease implicated in cancer.
  • Its precise role in tumorigenesis remains complex and multifaceted.

Purpose of the Study:

  • To provide a comprehensive review of ADAM15's dual functions in cancer.
  • To highlight novel regulatory mechanisms and therapeutic strategies targeting ADAM15.

Main Methods:

  • Literature review of ADAM15 research.
  • Analysis of exosomal communication, ncRNA regulation, and peptide-based therapeutics.
  • Systematic matrix of therapeutic strategies.

Main Results:

  • ADAM15 exhibits both pro- and anti-cancer activities.
  • Mechanisms include exosomal transfer, regulation by specific ncRNAs (miR-3174, miR-526b-5p, NCK1-AS1), and the antiangiogenic peptide AMEP.
  • A therapeutic strategy matrix covers small molecules, antibodies, RNA therapeutics, PROTACs, and combination therapies.

Conclusions:

  • ADAM15 presents a complex target for cancer therapy.
  • Understanding its multifaceted roles is crucial for developing effective treatment strategies.
  • Future research should focus on targeted interventions and combination therapies.
Keywords:
ADAM15cancerclinical trialsdrug discoverytherapeutic targetingtumor microenvironment

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...